Research analysts at UBS Group began coverage on shares of Surgery Partners (NASDAQ:SGRY) in a note issued to investors on Thursday, The Fly reports. The brokerage set a “neutral” rating on the stock.

Other research analysts have also recently issued research reports about the company. Zacks Investment Research raised Surgery Partners from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Thursday, August 16th. BidaskClub raised Surgery Partners from a “hold” rating to a “buy” rating in a research note on Tuesday, August 14th. ValuEngine raised Surgery Partners from a “hold” rating to a “buy” rating in a research note on Thursday, August 9th. Finally, Bank of America raised Surgery Partners from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 18th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $18.83.

SGRY stock traded up $0.02 during trading hours on Thursday, hitting $13.63. 216,700 shares of the stock traded hands, compared to its average volume of 331,597. Surgery Partners has a one year low of $7.55 and a one year high of $19.95. The stock has a market capitalization of $685.12 million, a P/E ratio of -16.23 and a beta of 2.02. The company has a quick ratio of 1.44, a current ratio of 1.57 and a debt-to-equity ratio of 1.72.

Surgery Partners (NASDAQ:SGRY) last announced its earnings results on Wednesday, November 7th. The company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.01). Surgery Partners had a negative net margin of 5.55% and a negative return on equity of 1.68%. The firm had revenue of $443.90 million for the quarter, compared to the consensus estimate of $440.38 million. During the same period in the prior year, the business earned ($0.02) EPS. The company’s quarterly revenue was up 44.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Surgery Partners will post -0.48 earnings per share for the current year.

In other news, insider Brandan Lingle sold 10,000 shares of the company’s stock in a transaction on Tuesday, August 28th. The stock was sold at an average price of $18.15, for a total transaction of $181,500.00. Following the completion of the sale, the insider now directly owns 20,393 shares of the company’s stock, valued at $370,132.95. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 8.20% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Wolverine Asset Management LLC lifted its holdings in shares of Surgery Partners by 493.2% during the second quarter. Wolverine Asset Management LLC now owns 70,163 shares of the company’s stock valued at $1,045,000 after purchasing an additional 58,336 shares during the last quarter. Highland Capital Management LP lifted its holdings in shares of Surgery Partners by 171.3% during the second quarter. Highland Capital Management LP now owns 323,700 shares of the company’s stock valued at $4,823,000 after purchasing an additional 204,400 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of Surgery Partners during the second quarter valued at $318,000. Dimensional Fund Advisors LP lifted its holdings in shares of Surgery Partners by 5.5% during the second quarter. Dimensional Fund Advisors LP now owns 571,218 shares of the company’s stock valued at $8,512,000 after purchasing an additional 29,643 shares during the last quarter. Finally, Bank of Montreal Can purchased a new stake in shares of Surgery Partners during the second quarter valued at $149,000. 97.81% of the stock is owned by institutional investors and hedge funds.

Surgery Partners Company Profile

Surgery Partners, Inc, through its subsidiaries, operates surgical facilities in the United States. The company operates through three segments: Surgical Facility Services, Ancillary Services, and Optical Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management.

Featured Article: 52-Week High/Low Prices For Stock Selection

The Fly

Analyst Recommendations for Surgery Partners (NASDAQ:SGRY)

Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.